v3.26.1
Earnings (Loss) per share (Tables)
 6 Months Ended
Jun. 30, 2026
Earnings Per Share [Abstract]  
Schedule of Earnings per Share
Basic and diluted earnings (loss) per share attributable to Teva’s ordinary shareholders for the
 
t
hree and
 six months ended June 30, 2026 and 2025, are calculated as follows:
 
 
  
Three Months Ended
 
  
Six Months Ended
 
 
  
June 30,
 
  
June 30,
 
 
  
(U.S. $ in millions except share and per
share data)
 
 
  
2026
 
 
2025
 
  
2026
 
 
2025
 
Basic earnings (loss) attributable to Teva’s ordinary shareholders (numerator):
  
Net income (loss) attributable to Teva’s ordinary shareholders
    $ (576 )    $ 282      $ (207 )    $ 497  
  
 
 
     
 
 
     
 
 
     
 
 
  
Shares (denominator):
            
Weighted average shares outstanding
      1,165        1,147        1,160        1,142  
  
 
 
     
 
 
     
 
 
     
 
 
  
Basic earnings (loss) attributable to Teva’s ordinary shareholders
    $ (0.49 )
 
    $ 0.25  
 
    $ (0.18 )    $ 0.43  
  
 
 
     
 
 
     
 
 
     
 
 
  
Diluted earnings (loss) attributable to Teva’s ordinary shareholders (numerator):
            
Net income (loss) attributable to Teva’s ordinary shareholders
    $ (576 )    $ 282      $ (207 )    $ 497  
  
 
 
     
 
 
     
 
 
     
 
 
  
Shares (denominator):
            
Weighted average shares outstanding
      1,165        1,147        1,160        1,142  
Diluted effect of stock options, RSUs and PSUs
      —         14        —        17  
  
 
 
     
 
 
     
 
 
     
 
 
  
Total dilutive shares outstanding
      1,165        1,161        1,160        1,159  
  
 
 
     
 
 
     
 
 
     
 
 
  
Diluted earnings (loss) attributable to Teva’s ordinary shareholders
    $ (0.49 )    $ 0.24      $ (0.18 )
 
    $ 0.43